Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Peter Impey

Patients’willingness to pay

Considerations when developing an appropriate pricing strategy in self-pay markets

Inizio

- PMLiVE

UK unveils plans for bigger medicines price squeeze

Company payments to government would rise steeply to 2021

- PMLiVE

Allergan builds on gene editing deal

Firm will co-develop CRISPR candidate for vision-threatening disorder

- PMLiVE

As ‘No Deal’ fears grow, pharma can’t rely on transition period

UK could still remain part of EMA 'club' until 2020 - but time is running out

- PMLiVE

Passion for science leads to promotion at Porterhouse Medical

It is with enormous pleasure that Porterhouse Medical announces the promotion of Rebecca Thomas to account manager.   Becky has a passion for science and gained a biological sciences degree from the...

Porterhouse Medical Group

- PMLiVE

Irritable Bowel Syndrome (IBS) patient insights

It’s common. It’s debilitating. We’re talking about IBS. In this issue of MAGNIFI, we explore the insights of patients suffering with IBS, while also looking into research around the HCP–patient...

IGNIFI

- PMLiVE

New appointment in Porterhouse Medical’s scientific services team.

Porterhouse Medical is delighted to welcome Devdutt Sharma to our scientific services team as associate medical writer. Dev has more than 5 years of scientific experience in an academic environment...

Porterhouse Medical Group

Regeneron and Bluebird sign $100m cell therapies deal

Six targets chosen from TCR and other cell therapy platforms

- PMLiVE

Almirall acquires Allergan’s dermatology portfolio for $650m

The pharma group buys four products along with Allergan's first-in-class antibiotic Seysara

- PMLiVE

Boehringer and partners set sights on cystic fibrosis gene therapy

Deal builds on 17 years work in UK academic consortium

- PMLiVE

How pharma can unlock the potential of influencer marketing

Building a successful campaign around influencer marketing

- PMLiVE

Cancer immunotherapy: What’s on the horizon?

Old and new therapies

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links